UiPath, a prominent enterprise automation software company listed on the New York Stock Exchange under the ticker symbol PATH, has announced that Mitsubishi Tanabe Pharma Corporation, a leading Japanese pharmaceuticals company, has adopted the UiPath Business Automation Platform to enhance their business operational efficiency beyond human labor capabilities.
Mitsubishi Tanabe Pharma is dedicated to providing hope for patients facing illnesses. However, the pharmaceutical industry struggles with developing effective drugs that meet the needs of patients, making new drug development more challenging each year. By implementing UiPath, Mitsubishi Tanabe Pharma is promoting digital technology reform in their new drug development and overall business productivity.
Since adopting UiPath in 2019, Mitsubishi Tanabe Pharma has created more than 500 workflows that automate various tasks, saving a total of 70,000 hours and producing significant results in operational efficiency. Automation has enabled several tasks that were previously unattainable by human labor.
For example, the Human Resources (HR) Department has entrusted software robots with the task of contacting prospective employee retirees every month to reduce workloads and drastically improve retiree satisfaction. In the research and development field, Mitsubishi Tanabe Pharma has developed workflows that add value to their business operations, such as crawling academic and society websites to send emails to the individual in charge when there is updated information and extracting necessary information from reports to support the creation of an application form that aggregates many reports that researchers prepare which afterwards are submitted to the proper medical authorities.
The RPA Center of Excellence was assumed by Mitsubishi Tanabe Pharma Provision Corporation, which consolidates all administrative tasks for companies under the entire group – including pharmaceutical information, accounting, general affairs, and HR – into a single point of contact. The Center of Excellence has created a unique training program to develop a wide range of citizen developers, including those who can develop workflows and determine which operations are suitable for automation. In collaboration with UiPath, they have developed and implemented a new learning curriculum to train advanced developers.
UiPath’s Co-Chief Executive Officer, Rob Enslin, expressed his satisfaction with their role in Mitsubishi Tanabe Pharma Group’s automation journey, stating that “Today’s automation goes well beyond RPA” which is the new way to operate and the new way to innovate. Mitsubishi Tanabe Pharma can future-proof their business and establish a hybrid human-digital workforce of the future by incorporating citizen development into their automation program.
UiPath aims to deliver the Fully Automated Enterprise™, where companies use automation to unlock their greatest potential. UiPath provides a comprehensive automation platform that combines the top Robotic Process Automation (RPA) solution with a full range of features, empowering organizations to quickly expand their digital business operations.
Leave a Reply